FDA panel Oks prostate drug
From Times Wire Reports
Federal health advisors have endorsed an experimental vaccine to treat advanced prostate cancer as safe and effective.
The Food and Drug Administration advisors voted unanimously to say Provenge is safe. They then voted 13 to 4 to say there was substantial evidence it works in treating advanced prostate cancer that no longer responds to hormone treatment.
The FDA isn’t required to follow the advice of its advisory committees, but it usually does. A final FDA decision on whether to approve Provenge, also called sipuleucel-T, is expected May 15.
